Back to SGEN Stock Lookup
Pages: 1 2 3 »» Last Page

SGEN – Analyst Ratings

Mar 10, 2014 10:06 AM UPDATE: H.C. Wainwright Starts Seattle Genetics (SGEN) at Buy
Feb 24, 2014 09:16 AM BofA/Merrill Lynch Reinstates Seattle Genetics (SGEN) at Underperform
Feb 12, 2014 07:43 AM Needham & Company Upgrades Seattle Genetics (SGEN) to Buy; Could Be Next Large Cap Drug Co.
Dec 9, 2013 09:38 AM Piper Jaffray Reiterates Underweight Rating on Seattle Genetics (SGEN)
Sep 5, 2013 01:14 PM Bernstein Names Potential Biotech M&A Targets (PTLA) (VRTX) (ALXN)
Jun 26, 2013 07:37 AM Seattle Genetics (SGEN): Premature to Draw Link Between Adcetris and Pancreatitis - Jefferies
May 7, 2013 03:57 PM Goldman Sachs Resumes Seattle Genetics (SGEN) at Neutral
Feb 13, 2013 07:54 AM Needham & Company Downgrades Seattle Genetics (SGEN) to Hold
Nov 13, 2012 06:53 AM Credit Suisse Starts Seattle Genetics (SGEN) at Outperform
Nov 9, 2012 09:45 AM Guggenheim Starts Seattle Genetics (SGEN) at Neutral
Nov 8, 2012 06:52 AM Cantor Fitzgerald Downgrades Seattle Genetics (SGEN) to Sell
Sep 10, 2012 12:55 PM UBS on U.S. Biotechnology - Updating Outlook on Covered Stocks (GILD, AMGN, BIIB, CELG, INCY, IDIX, VRTX, SGEN)
Sep 7, 2012 09:45 AM UPDATE: Oppenheimer Downgrades Seattle Genetics (SGEN) to Perform; Valuation Call
Jul 18, 2012 01:06 PM Needham & Company Maintains a 'Buy' on Seattle Genetics (SGEN); Q2 Preview of Adcetris Sales
Jul 5, 2012 07:44 AM ThinkEquity Starts Seattle Genetics (SGEN) at Buy
Jul 2, 2012 06:44 AM Piper Jaffray Downgrades Seattle Genetics (SGEN) to Underweight
Jun 8, 2012 07:50 AM Needham & Company Reiterates a 'Buy' on Seattle Genetics (SGEN); Raising Price Target After ASCO Meeting Review
Jun 4, 2012 08:22 AM Oppenheimer Comments on Seattle Genetics (SGEN) After 2012 ASCO
May 18, 2012 01:48 PM UBS Raises PT on Seattle Genetics (SGEN) on Adcetris Label Expansion Opportunities
May 9, 2012 12:49 PM Leerink Swann Maintains an 'Outperform' on Seattle Genetics (SGEN); Modest Growth, but Opportunities in Pipeline
Feb 14, 2012 09:33 AM Canaccord Genuity Maintains a 'Sell' on Seattle Genetics (SGEN); Uncertain 2012 Adcetris Sales Outlook
Feb 14, 2012 08:31 AM Needham & Company Reiterates a 'Buy' on Seattle Genetics (SGEN); Impressive First Full Quarter of Adcetris Sales
Feb 10, 2012 10:48 AM Canaccord Genuity Maintains a 'Sell' on Seattle Genetics (SGEN); Q4 Adcetris Sales Expectations
Jan 6, 2012 10:44 AM Needham & Company Reiterates a 'Buy' on Seattle Genetics (SGEN); 2012 Preview
Jan 5, 2012 08:41 AM Canaccord Genuity Maintains a 'Sell' on Seattle Genetics (SGEN); Increasing Adcetris Estimates, But Still Disconnect Between Valuation & Potential Sales
Jan 4, 2012 11:12 AM Goldman Sachs Highlights Best and Worst in Biotech for 2012
Dec 23, 2011 07:35 AM Needham & Company 2012 Biotech Preview
Dec 15, 2011 11:41 AM Biotech M&A Will Be In Focus in 2012 - Goldman
Dec 14, 2011 07:40 AM Needham & Company Reiterates a 'Buy' on Seattle Genetics (SGEN); Adcetris Data in Combination with AVD Supportive of Potential Role in Front Line Therapy
Dec 9, 2011 07:39 AM WJB Capital Starts Seattle Genetics (SGEN) at Sell
Nov 11, 2011 09:12 AM Needham & Company Assumes Coverage on Seattle Genetics (SGEN) at Buy; 3Q11 Review and ASH Meeting Preview
Nov 4, 2011 07:46 AM Piper Jaffray Downgrades Seattle Genetics (SGEN) to Neutral
Oct 25, 2011 11:47 AM Canaccord Genuity Q3 Biotech Results Preview
Oct 21, 2011 09:01 AM Canaccord Genuity Maintains a 'Sell' on Seattle Genetics (SGEN); Adcetris H2 Sales Estimate Preview
Oct 13, 2011 11:07 AM UBS maintains a 'Neutral' on Seattle Genetics (SGEN); Thoughts on Near-, Mid-, and Long-Term
Oct 12, 2011 08:57 AM Jefferies Raises Expectations on Seattle Genetics (SGEN) Adcetris Sales Following Talks with EAP Centers
Oct 5, 2011 09:15 AM Summer Street Starts Seattle Genetics (SGEN) at Sell
Oct 3, 2011 08:43 AM Goldman Sachs Resumes Seattle Genetics (SGEN) at Neutral
Sep 19, 2011 03:39 PM RBC Doubles '11 Sales Estimate on Seattle Genetic’s (SGEN) Adcetris, Cites Recent Survey
Sep 16, 2011 07:52 AM Madison Williams Starts Seattle Genetics (SGEN) at Sell
Aug 23, 2011 09:50 AM Jefferies Ups PT on Seattle Genetics (SGEN) to $25 Following Adcetris Call; Adjusts Numbers, Outlook
Aug 23, 2011 08:30 AM Canaccord Genuity Maintains a 'Sell' on Seattle Genetics (SGEN); Adcetris Launch Ahead
Aug 22, 2011 03:06 PM Needham & Company Reiterates a 'Buy' on Seattle Genetics; As the School Year Begins, So Does Commercial Life for SGEN
Aug 22, 2011 08:43 AM Canaccord Genuity Maintains a 'Sell' on Seattle Genetics (SGEN); Adcetris Label Supports Limited Market Opportunity
Aug 22, 2011 08:14 AM Jefferies Comments on FDA Approval of Seattle Genetics (SGEN) Adcetris, Better-Than-Expected
Aug 8, 2011 07:23 AM Citadel Securities Starts Seattle Genetics (SGEN) at Reduce; Adcetris Approvable, But Market Opportunity Appears Overestimated
Jul 19, 2011 08:31 AM Canaccord Genuity Maintains a 'Sell' on Seattle Genetics (SGEN); Profile Shift Expected to Weigh on Shares
Jul 15, 2011 10:03 AM Jefferies Boosts PT on Seattle Genetics (SGEN) Following FDA Panel Vote; Is Buyer on Weakness
Jul 12, 2011 03:33 PM Needham & Company maintains a 'Buy' on Seattle Genetics (SGEN); FDA Briefing Documents for the BLAs of ADCETRIS
Jul 11, 2011 09:19 AM Chardan Capital Downgrades Seattle Genetics (SGEN) to Sell
Pages: 1 2 3 »» Last Page

Back to SGEN Stock Lookup